Cyclosporin a Initially as the Only Immunosuppressant in 34 Recipients of Cadaveric Organs: 32 Kidneys, 2 Pancreases, and 2 Livers

Calne, R. Y.; Rolles, K; Thiru, S; McMaster, P; Craddock, Graham N.; Aziz, Sina; White, David J.; Evans, David B.; Dunn, D. C.; Henderson, Robin; Lewis, P. R.

doi:10.1016/s0140-6736(79)92440-1

Cited by 934 publications

(316 citation statements)

References 8 publications

Supporting

Mentioning

293

Contrasting

Unclassified

Order By: Relevance

“…1 However, its nephrotoxicity and other limitations have stimulated a continuing search for alternative agents. We report here the first clinical trials in liver recipients of a new drug that is not related chemically to cyclosporin or to other standard immunosuppressants.…”

Section: Introductionmentioning

confidence: 99%

Fk 506 for Liver, Kidney, and Pancreas Transplantation

Fung²,

et al. 1989

View full text Add to dashboard Cite

Summary FK 506 was given for immunosuppression in 14 liver recipients. The drug was used in the first 10 cases because the recipients under conventional immunosuppression had rejection, nephrotoxicity, or both. This salvage therapy was successful in 7 of the 10 attempts. 2 of the 10 patients in the original salvage group as well as 4 new patients underwent fresh orthotopic liver transplantation under FK 506 plus low-dose steroids from the outset. None of these 6 patients had rejection although 1 with preexisting cor pulmonale and coronary atherosclerosis died of a myocardial infarction. In addition, 2 of the 14 liver recipients were given cadaveric kidneys, either from the same donor or from a different donor, and a third was given a pancreas as well as a kidney from the liver donor. There were no rejections of the kidney and pancreas grafts, and serious side-effects were not encountered.

show abstract

Section: Introductionmentioning

confidence: 99%

Fk 506 for Liver, Kidney, and Pancreas Transplantation

Fung²,

et al. 1989

View full text Add to dashboard Cite

show abstract

“…3,4 Calne et al 3,5 reported a putative acute nephrotoxic syndrome leading to anuria or oliguria in 11 out of 32 patients treated with CyA. They thought that this problem was ameliorated by inducing forced diuresis with fluids and mannitol.…”

Section: Introductionmentioning

confidence: 99%

Nephrotoxicity of Cyclosporin a in Liver and Kidney Transplant Patients

1981

View full text Add to dashboard Cite

SummaryIn six of twelve orthotopic liver recipients nephrotoxicity was noted after 13-22 days of treatment with 16.3±2.9 (SEM) mg/kg per day of cyclosporin A (CyA). With a decrease in the daily CyA dose to 9.2±2.3 (SEM) mg/kg kidney function returned to normal. No hepatic rejections occurred on this lowered CyA dose. In 4 out of 66 kidney recipients a switch from a CyA dose of 5.2-10.7 mg/kg daily to azathioprine was done 4-8 months after transplant because of unsatisfactory kidney function, suspected to be due to nephrotoxicity. In three patients, this resulted in an improved graft function. A fourth transplant was lost to an irreversible rejection 13 days later. Thus CyA is nephrotoxic but this toxicity is easily reversed, even after many months of treatment, and the ease with which this complication can be managed suggests that nephrotoxicity should not diminish the high expectations that transplant surgeons have for CyA.

show abstract

“…It has been systemically used since 1979 in preventing transplant and for immunological diseases (Calne et al 1979). In ophthalmology, it is used specially for decreasing cases of rejection of corneal implant and transplant (Calatayud et al 2001).…”

Section: Discussionmentioning

confidence: 99%

Effects of topical 0.2% Cyclosporine A on corneal neovascularization induced by xenologous amniotic membrane implantation into a corneal stroma micropocket of rats

et al. 2008

View full text Add to dashboard Cite

RESUMO.-[Efeitos do uso tópico da Ciclosporina A (CsA) 0,2% na neovascularização corneal induzida pelo implante de membrana amniótica xenógena em microbolsa no estroma da córnea de ratos.] Este estudo teve como objetivo a avaliação dos efeitos tópicos da Ciclosporina a 0,2% (CsA) sobre a neovascularização corneana de ratos após implante cirúrgico de membrana amniótica eqüina em microbolsa do estroma corneana. O implante da membrana foi feito bilateralmente em 90 ratos. O tratamento com The objective of the study was to evaluate the topical effects of 0.2% Cyclosporine A (CsA) on corneal neovascularization of rats following surgical implantation of equine amniotic membrane into a corneal stroma micropocket. The implantation of xenologous amniotic membrane was performed bilaterally in 90 rats. In the same day of the surgery each right eye started receiving topical CsA twice a day. The left eye received no medication and served as a control. The evaluation of corneal neovascularization was performed by computerized image analysis and histopathological evaluation at 1, 3, 7, 15, 30 and 60 days postoperatively. For the image analysis 10 animals were used per time period, and for the histopathological examination, five animals were used per time period. Image analysis found that corneal neovascularization began on the 3rd postoperative day, reached its peak on the 7th day, and then progressively and rapidly decreased. Statistic analysis indicated that neovascularization of the CsA treated eye on the 7th day was significantly higher than that observed in untreated eyes. On the 30th day, however, this pattern was reversed with the neovascularization observed in the CsA treated eyes declining to the low levels observed on the 3rd day. The degree of neovascularization in the untreated eyes on the 30th day declined to the baseline levels found on day 3 at the 60th day. Histopathological analysis indicated that deposition of collagen in the implanted tissue was completed by the 15th day. Therefore, we concluded that (1) equine amniotic membrane in rat corneal stroma produced an intense neovascularization until the 15th day postoperatively and then regressed, (2) deposition of collagen of the implanted tissue was completed on the 15th day postoperatively, and (3) use of CsA was associated with increase in the corneal neovascularization initially, followed by a quick and intense regression. CsA iniciou-se no mesmo dia da cirurgia, nos olhos direitos dos animais, duas vezes ao dia. Os olhos esquerdos não receberam nenhum tratamento e serviram de controle. A avaliação da neovascularização corneana foi feita por análi-se de imagem computadorizada e por exame histopatológi-co aos dias 1, 3, 7, 15, 30 e 60 de pós-cirúrgico. Para a análise de imagem foram utilizados 10 animais por período, e para o exame histopatológico, 5 por período. A análise de imagem demonstrou que a neovascularização iniciou-se no 3° dia pós-cirúrgico, alcançou seu pico no 7° dia e então regrediu rápida e progressivamente até o 60° dia. A análise estatística ...

show abstract

Cyclosporin a Initially as the Only Immunosuppressant in 34 Recipients of Cadaveric Organs: 32 Kidneys, 2 Pancreases, and 2 Livers

Cited by 934 publications

References 8 publications

Fk 506 for Liver, Kidney, and Pancreas Transplantation

Fk 506 for Liver, Kidney, and Pancreas Transplantation

Nephrotoxicity of Cyclosporin a in Liver and Kidney Transplant Patients

Effects of topical 0.2% Cyclosporine A on corneal neovascularization induced by xenologous amniotic membrane implantation into a corneal stroma micropocket of rats

Contact Info

Product

Resources

About